Overview

Public Biotech

Clinical-stage biopharma developing psilocybin-assisted therapy (PSX-001) for generalized anxiety disorder and cannabinoid combinations for sleep apnea. Positive Phase 2 results in 2025 for both programs.

Visit Website

Wilmington, DE

$75M
Market Cap
2015
Founded
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline

No clinical trials on record